- Abstract Number: 1669
Will Investigators Enroll? A Vignette Study to Gauge Investigator Equipoise in a Trial of Surgery vs. Nonoperative Therapy in Subjects with Meniscal Tear and Persistent Pain Following Physical Therapy
- Abstract Number: 2262
Window of Opportunity in the Treatment of Rheumatoid Arthritis – Interstitial Lung Disease with Abatacept. National Multicenter Study of 526 Patients
- Abstract Number: 2124
WITHDRAWN
- Abstract Number: 1500
Work-Related Disability and Function in Systemic Lupus Erythematosus (SLE): Outcomes of an Exploratory Study from Different Canadian Centres
- Abstract Number: 2227
Worrisome Mortality Trends over 20 Years Among Patients with Underlying Ischemic Heart Disease and Rheumatoid Arthritis
- Abstract Number: 1800
WWC1 Regulates Type I Interferon Production Through Modulation of cGAS-STING Signaling in Keratinocytes
- Abstract Number: 2599
Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes
- Abstract Number: 0878
YY1 a Potential Modulator of IL17/IL23 Axis in Psoriasis Disease
- Abstract Number: 0865
Z’s and Knees: Associations of Participant-reported and Objective Sleep Measures with Pain Among US Veterans with Osteoarthritis of the Knee
- Abstract Number: 0877
Zasocitinib (TAK-279) Displays High Levels of TYK2 Inhibition and No Inhibition of JAK 1/3 Compared with Licensed TYK2 and JAK Inhibitors
- Abstract Number: 1477
Zasocitinib (TAK-279), a Highly Selective Oral Tyrosine Kinase 2 (TYK2) Inhibitor, Elicits Early Skin Responses and Minimal Disease Activity in Patients with Active Psoriatic Arthritis: Results from a Randomized Phase 2b Study
- Abstract Number: 1131
Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
- Abstract Number: 2584
Zasocitinib (TAK-279), an Oral, Selective Tyrosine Kinase 2 Inhibitor: Achievement of Remission and Additional Improvements in Disease Activity in Patients with Psoriatic Arthritis Enrolled in a Phase 2b Trial
- Abstract Number: 0658
Zetomipzomib (KZR-616), a First-in-Class Selective Immunoproteasome Inhibitor, Demonstrated Improvements in SLE/LN Disease Measures and Biomarkers in Patients with Highly Active SLE or Nephrotic Range Proteinuria in the Open-label Phase 1b/2 MISSION Study
- Previous Page
- 1
- …
- 180
- 181
- 182